COMP <GO>
COR vs ABBV // RSI-14 & 200D SMA MOMENTUM
Cencora Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: COR 4
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $330.53 (+1.91%) • MKT CAP: $63.07B
rsi-technicals
53.8
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
rsi-technicals
65.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.60% | 70.20% | -66.60 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.80% | 29.00% | -2.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.6x | 33.3x | -11.70 | COR | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 3.47% | +1.61 | COR | /fcf-yield <GO> |
| Operating Margin | 0.80% | 24.60% | -23.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.50% | 6.90% | -6.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 9.30% | 8.60% | +0.70 | COR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.69% | 2.27% | -1.58 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.27 | 5.33 | -0.06 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 53.8 | 65.1 | -11.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.8x | 113.1x | -75.30 | COR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.07B | $513.86B | -$450.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COR REV | ABBV REV | COR GROSS % | ABBV GROSS % | COR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $321.33B | $61.16B | 3.6% | 70.2% | $3.21B | $17.82B |
| FY 2024 | $293.96B | $56.33B | 3.4% | 70.0% | $3.00B | $17.83B |
| FY 2023 | $262.17B | $54.32B | — | — | -$7.89B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COR // BETA 0.88
ABBV // BETA 1.15